Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04524221 | PTG-100 for Patients With Celiac Disease | PHASE1 | COMPLETED | 12 | — | — | Feb 26, 2021 | Apr 3, 2022 | May 23, 2022 | 1 | United States |
Percentage change from baseline to Week 6 in villous height-to crypt depth (Vh:Cd) ratio
| Arm | Type | Description |
|---|---|---|
| PTG-100 | EXPERIMENTAL | Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. |
| Placebo | PLACEBO_COMPARATOR | Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. |
| Name | Type | Description |
|---|---|---|
| PTG-100 | DRUG | PTG-100, 600mg taken twice daily in capsule form for 42 days |
| Placebo | DRUG | Placebo taken twice daily in capsule form for 42 days |
Inclusion Criteria: * Diagnosis of celiac disease Exclusion Criteria: * Active GI disease or history of clinically significant diseases * Diagnosis of Crohn's disease or ulcerative colitis.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
| TScan Therapeutics, Inc. | TCRX | 1 | — | Undisclosed |